Boosting the NAD+ Levels in Older Individuals Via Nicotinamide Riboside Supplementation and Exercise Training to Promote Metabolic Health

Status: Recruiting
Location: See location...
Intervention Type: Dietary supplement
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

The prevalence of age-related chronic diseases (like obesity, type 2 diabetes and cardiovascular diseases) is mounting worldwide, reaching pandemic proportions. These age-related chronic diseases are associated with diminished skeletal muscle mitochondrial function in humans. Nicotinamide adenosine dinucleotide (NAD) is a coenzyme that regulates mitochondrial function, therefore, plays an important role in energy metabolism. Importantly, it has been shown that high cellular NAD+ levels as well as a high NAD+/NADH ratio promote metabolic and mitochondrial health. In contrast, NAD+ bioavailability declines upon aging in humans as well as in animal models of metabolic disorders and type 2 diabetes. These findings fuel the notion of boosting the NAD+ bioavailability in order to improve metabolic disturbances and mitochondrial dysfunction in aged individuals. Supplementation with nicotinamide riboside (NR), a naturally occurring form of vitamin B3, boosts cellular NAD+ levels. However, in contrast to animal studies, NR supplementation in humans has so far been unsuccessful in improving skeletal muscle mitochondrial function, exercise capacity or insulin sensitivity. Interestingly, Recently, it has been suggested that metabolic conditions where NAD+ levels become limited, is needed for NR supplementation to exert beneficial health effects. This metabolic condition could be achieved by exercise. However, studies combining NR and exercise are lacking, and that is why we will perform the present study.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 60
Maximum Age: 80
Healthy Volunteers: t
View:

• Participants are able to provide signed and dated written informed consent prior to any study specific procedures

• Aged ≥ 60 and ≤ 80 years

• Body mass index (BMI) 25 - 35 kg/m2

• Stable dietary habits (no weight loss or gain \> 5 kg in the past 3 months)

• No signs of active cardiovascular disease, liver or kidney malfunction

Locations
Other Locations
Chile
Finis Terrae University
RECRUITING
Santiago
Contact Information
Primary
Rodrigo Mancilla, PhD
rmancilla@uft.cl
+56953676588
Time Frame
Start Date: 2024-03-01
Estimated Completion Date: 2026-03
Participants
Target number of participants: 28
Treatments
Experimental: NR+EXTR
This arm will ingest NR orally and perform exercise training
Placebo_comparator: PLA+EXTR
This arm will ingest placebo orally and perform exercise training
Related Therapeutic Areas
Sponsors
Leads: Finis Terrae University

This content was sourced from clinicaltrials.gov